(4Z)-4-[(4-fluorophenyl)methylidene]-2-naphthalen-2-yl-1,3-oxazol-5-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (4Z)-4-[(4-fluorophenyl)methylidene]-2-naphthalen-2-yl-1,3-oxazol-5-one
• 化学式: C₂₀H₁₂FNO₂
• 分子量: 317.3
• InChiKey: YSMGCLCLIYIGRJ-WQRHYEAKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] PHARMACEUTICALLY ACTIVE PYRAZOLO-PYRIDONE MODULATORS OF DCN1/2-MEDIATED CULLIN NEDDYLATION<br/>[FR] MODULATEURS DE PYRAZOLO-PYRIDONE PHARMACEUTIQUEMENT ACTIFS DE NÉDDYLATION INDUITE PAR DCN1/2
  申请人：UNIV KENTUCKY RES FOUND

  公开号：WO2020257790A1

  公开（公告）日：2020-12-24

  A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

  提供了一种由DCN1/2介导的cullin泛素化调节剂；一种治疗与DCN1和/或UBC12功能失调相关的疾病、阿尔茨海默病、其他神经退行性疾病、细菌感染或病毒感染的方法；以及一种治疗癌症的方法。DCN1/2介导的cullin泛素化调节剂包括本文披露的一种符合式I的化合物。该方法包括向哺乳动物施用符合式I的化合物的治疗有效剂量。本文还提供了一种包括符合式I的化合物的治疗有效剂量或其药学上可接受的盐以及药学上可接受的载体的药物组合物。
• PHARMACEUTICALLY ACTIVE PYRAZOLO-PYRIDONE MODULATORS OF DCN1/2-MEDIATED CULLIN NEDDYLATION
  申请人：UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

  公开号：US20220280488A1

  公开（公告）日：2022-09-08

  A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.